Comera Life Sciences Holdings, Inc. (CMRA)

OTCMKTS: CMRA · Delayed Price · USD
0.0222
0.00 (0.00%)
Jul 18, 2024, 4:00 PM EDT - Market closed
Market Cap 682.38K
Revenue (ttm) 1.00M
Net Income (ttm) -84.25M
Shares Out 30.74M
EPS (ttm) -4.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,237
Open 0.0222
Previous Close n/a
Day's Range n/a
52-Week Range 0.0210 - 0.7390
Beta 0.14
Analysts n/a
Price Target n/a
Earnings Date Nov 9, 2023

About CMRA

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company’s lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 13
Stock Exchange OTCMKTS
Ticker Symbol CMRA
Full Company Profile

Financial Performance

In 2022, CMRA's revenue was $633,102, an increase of 97.95% compared to the previous year's $319,832. Losses were -$24.04 million, 354.3% more than in 2021.

Financial Statements

News

Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option

WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technolog...

7 months ago - GlobeNewsWire

Comera Life Sciences Announces Process Exploring Strategic Alternatives

WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicine...

8 months ago - GlobeNewsWire

Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access...

8 months ago - GlobeNewsWire

Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –

9 months ago - GlobeNewsWire

Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference

WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access...

9 months ago - GlobeNewsWire

Comera Life Sciences Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities

Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies

1 year ago - GlobeNewsWire

Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –

1 year ago - GlobeNewsWire

Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform

WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access...

1 year ago - GlobeNewsWire

Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients

– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs –

1 year ago - GlobeNewsWire

Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights

– Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –

1 year ago - GlobeNewsWire

Comera Life Sciences to Participate in Four Upcoming Conferences

WOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biol...

1 year ago - GlobeNewsWire

Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology

Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™ platform.

1 year ago - GlobeNewsWire

Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –

1 year ago - GlobeNewsWire

Comera Life Sciences to Present at 22nd Annual PepTalk Conference

WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biolo...

1 year ago - GlobeNewsWire

Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

1 year ago - GlobeNewsWire

Comera Life Sciences to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

1 year ago - GlobeNewsWire

Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –

1 year ago - GlobeNewsWire

Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study

WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

1 year ago - GlobeNewsWire

Comera Life Sciences Expands Woburn Operations

Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event

1 year ago - GlobeNewsWire

Comera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business Solutions

WOBURN, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biolo...

2 years ago - GlobeNewsWire

Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022

WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

2 years ago - GlobeNewsWire

Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform

WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, ...

2 years ago - Business Wire

Comera Life Sciences Appoints Michael Campbell as Executive Vice President and Chief Financial Officer

WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, ...

2 years ago - Business Wire

What's Going On With OTR Acquisition Stock Today?

OTR Acquisition Corp (NASDAQ: OTRA) shares are trading higher Wednesday after the company filed a Form 8-K with the U.S. Securities and Exchange Commision. The move appears to be related to the high n...

2 years ago - Benzinga

Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation

WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and...

2 years ago - Business Wire